Quantitative clinical pharmacology and patient-centered healthcare technologies: perspectives 2030 ; Количественная клиническая фармакология и пациент-ориентированные технологии здравоохранения: перспективы 2030

Authors: V. I. Petrov, B. E. Tolkachev, В. И. Петров, Б. Е. Толкачев

Contributors: The study was performed without external funding., Работа выполнена без спонсорской поддержки.

Source: Regulatory Research and Medicine Evaluation; Том 12, № 2 (2022); 205-213 ; Регуляторные исследования и экспертиза лекарственных средств; Том 12, № 2 (2022); 205-213 ; 3034-3453 ; 3034-3062

Subject Terms: оценка технологий здравоохранения, population pharmacokinetic modelling, precision medicine, clinical pharmacology, health technology assessment, популяционное фармакокинетическое моделирование, прецизионная медицина, клиническая фармакология

File Description: application/pdf

Relation: https://www.vedomostincesmp.ru/jour/article/view/430/774; https://www.vedomostincesmp.ru/jour/article/downloadSuppFile/430/252; Клиническая фармакология в здравоохранении, образовании и науке. Качественная клиническая практика. 2020;(2S):7–66. https://doi.org/10.37489/2588-0519-2020-S2; Mentré F, Friberg LE, Duffull S, French J, Lauffenburger DA, Lang Li, et al. Pharmacometrics and systems pharmacology 2030. Clin Pharmacol Ther. 2020;107(1):76–8. https://doi.org/10.1002/cpt.1683; Pacanowski M, Liu Q. Precision Medicine 2030. Clin Pharmacol Ther. 2020;107(1):62–4. https://doi.org/10.1002/cpt.1675; Denny JC, Collins FS. Precision medicine in 2030—seven ways to transform healthcare. Cell. 2021;184(6):1415–9. https://doi.org/10.1016/j.cell.2021.01.015; Allegaert K, Flint R, Smits A. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Expert Opin Drug Metab Toxicol. 2019;15(9):735–49. https://doi.org/10.1080/17425255.2019.1655540; Mehrotra N, Bhattaram A, Earp JC, Florian J, Krudys K, Lee JE, et al. Role of quantitative clinical pharmacology in pediatric approval and labeling. Drug Metab Dispos. 2016;44(7):924–33. https://doi.org/10.1124/dmd.116.069559; Holford N, Karlsson MO. Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum. Clin Pharmacol Ther. 2007;82(1): 103–5. https://doi.org/10.1038/sj.clpt.6100231; Jean D, Naik K, Milligan L, Hall S, Huang SM, Isoherranen N, et al. Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision-making—A workshop summary. CPT: Pharmacometrics Syst Pharmacol. 2021;10(11):1271–5. https://doi.org/10.1002/psp4.12706; Brouwer KLR, Schmidt S, Floren LC, Johnson JA. Clinical pharmacology education — the decade ahead. Clin Pharmacol Ther. 2020;107(1):37–9. https://doi.org/10.1002/cpt.1652; Van Driest SL, Choi L. Real-world data for pediatric pharmacometrics: can we upcycle clinical data for research use? Clin Pharmacol Ther. 2019;106(1):84–6. https://doi.org/10.1002/cpt.1416; Venkatakrishnan K, Benincosa LJ. Diversity and inclusion in drug development: rethinking intrinsic and extrinsic factors with patient centricity. Clin Pharmacol Ther. Published online September 22, 2021. https://doi.org/10.1002/cpt.2416; Swift B, Jain L, White C, Chandrasekaran V, Bhandari A, Hughes DA, Jadhav PR. Innovation at the intersection of clinical trials and real-world data science to advance patient care. Clin Transl Sci. 2018;11(5):450–60. https://doi.org/10.1111/cts.12559; Shahin MH, Abdel-Rahman S, Hartman D, Johnson JA, Mitchell DY, Reynolds KS, et al. The patient-centered future of clinical pharmacology. Clin Pharmacol Ther. 2020;107(1):72–5. https://doi.org/10.1002/cpt.1681; Hill-McManus D, Marshall S, Liu J, Willke RJ, Hughes DA. Linked pharmacometric-pharmacoeconomic modeling and simulation in clinical drug development. Clin Pharmacol Ther. 2021;110(1):49–63. https://doi.org/10.1002/cpt.2051; https://www.vedomostincesmp.ru/jour/article/view/430

Availability: https://www.vedomostincesmp.ru/jour/article/view/430
https://doi.org/10.30895/1991-2919-2022-12-2-205-213

Популяционное фармакокинетическое моделирование как обоснование особенностей практического применения инъекций палиперидонапальмитата трехмесячного действия

Authors: Оленева, Е.В., Рывкин, П.В., Ладыженский, М.Я.

Source: Современная терапия психических расстройств, Vol 2017, Iss 2 (41), Pp 14-23 (2017)

Subject Terms: шизофрения, инъекционный палиперидона пальмитат трехмесячного действия, популяционное фармакокинетическое моделирование, schizophrenia, injectable paliperidone palmitate three months action, population pharmacokinetic modeling, Neurology. Diseases of the nervous system, RC346-429, Medicine

File Description: electronic resource

Relation: http://psypharma.ru/ru/populyacionnoe-farmakokineticheskoe-modelirovanie-kak-obosnovanie-osobennostey-prakticheskogo; https://doaj.org/toc/2306-4137

Access URL: https://doaj.org/article/21dcc327c2b547e49c2e87709b6d84c0